People under 40 will be offered an alternative to the Oxford/AstraZeneca vaccine where possible and while infection rates remain low, following a recommendation from government advisers.
It comes after the Joint Committee on Vaccination and Immunisation (JCVI) reviewed the speed and uptake of Covid vaccines in the UK and the latest figures on very rare blood clots after first shots of the AstraZeneca vaccine.
With the vaccination programme going well and case rates low, the chances of a major surge in hospitalisations and deaths have receded, leading advisers to believe a more precautionary approach can now be taken in 30- to 39-year-olds by offering the Pfizer/BioNTech or NIH/Moderna shots when available.
UK and European regulators have recorded a small number of people who have developed unusual blood clots with low platelets after receiving the AstraZeneca vaccine. Further cases have been reported in the US following the Johnson & Johnson jab, which is based on a similar technology.